Recruiting clinical research volunteers (stage 2 and 3 non-small cell lung cancer)
The Hong Kong United Oncology Centre is currently conducting an international Phase III clinical trial. If you are a patient with resectable stage II to IIIB (N2) non-small cell lung cancer (NSCLC), please contact us. We will conduct an initial assessment to determine your eligibility for this clinical trial. Medication and imaging scans are free of charge. However, patients must understand the purpose of the study and any potential risks involved.
Research name
A Phase 3, randomized, open-label study investigating the use of postoperative pembrolizumab alone or in combination with MK-2870 in subjects with resectable Stage II to IIIB (N2) non-small cell lung cancer (NSCLC) who did not achieve a pathological complete response (pCR) after receiving neoadjuvant pembrolizumab and platinum-based doublet chemotherapy.
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants
ClinicalTrials.gov Identifier: NCT06312137 (view detailed research data)
Patient eligibility
- Patients with resectable stage II to IIIB (N2) non-small cell lung cancer (NSCLC)
- Patients with resectable stage II to IIIB (N2) non-small cell lung cancer (NSCLC) who have received preoperative Pembrolizumab and platinum chemotherapy but have not achieved complete pathological remission (pCR) after surgery
- Patient With Resectable Stage II to IIIB (N2) NSCLC
- Patient With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery
Research remuneration
Related treatment drugs, image scans and doctor's consultations are free of charge
Research process
If you are eligible to participate in this research, you will use：
- Pembrolizumab and platinum combination chemotherapy treatment, and underwent surgery. Then use the research drug MK-2870 in combination with Pembrolizumab for treatment or Pembrolizumab alone for treatment.
- The research drug MK-2870 is used in combination with Pembrolizumab for treatment or Pembrolizumab alone for treatment.
Related risks
During the study period, you may have discomfort and risk due to Pembrolizumab and platinum chemotherapy treatment or surgery or MK-2870 combined with Pembrolizumab treatment or Pembrolizumab treatment. Discomfort and risk may vary from person to person.
Contact method
Interested participants can contact us through the following methods for further understanding：
- WhatsApp：5518 2992
- Telephone：+852 2386 8002
- Email：Enquiry@hkuoc.hk
- WeChat: hkuoc23868002
Related resources
Inquire about more research projects：Clinical Research Page of the United Cancer Centre of Hong Kong
Learn more about non-small cell lung cancer:Hong Kong Hospital Authority-Lung Cancer Information
Research sponsor
Research sponsor: Merck Sharp & Dohme LLC